3 ml tirzepatide 149.00 | --- 27 mg / --- 3 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1) Tirzepatide: Injection Home Kit –

PLoS ONE 11 , e0162590

ISBN 978-90-5702-597-6

(Study: Blonde et al., 2017) Cardiovascular Benefits: Beyond weight loss, both drugs have shown significant cardiovascular advantages, reducing the risk of heart-related complications in individuals with obesity and associated comorbidities

Shima Hadidchi provides ongoing support and guidance to help her patients stay on track

It is no longer a seasonal trade

Indications and Usage for Imcivree IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged [ see Dosage and Administration (2.1)]: 4 years and older with acquired hypothalamic obesity (HO) 2 years and older with syndromic or monogenic obesity due to: o Bardet-Biedl syndrome (BBS) o Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)